- Oops!Something went wrong.Please try again later.
- Oops!Something went wrong.Please try again later.
Stocks were down Monday morning even after encouraging comments on Johnson & Johnson’s vaccine from Dr. Anthony Fauci.
Stocks were down Monday morning even after encouraging comments on Johnson & Johnson’s vaccine from Dr. Anthony Fauci.
The "Hospital Linen Supply and Management Services - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
The "Pork Meat - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Dublin, May 07, 2021 (GLOBE NEWSWIRE) -- The "United States Dental Market By Segments, Types, Expenses, End Users (Private, Public), Company Analysis, Forecast" report has been added to ResearchAndMarkets.com's offering. United States Dental Market is expected to be $30.59 Billion by 2027, from $15.57 Billion in 2020, growing at a CAGR of 10.13% during 2020-2027 The factors that are expected to drive the demands of the dental equipment industry in the USA are: Cosmetic surgeryThe ageing of the American populationAdvancement in dental procedure due to advanced technology Some other factors may include poor oral hygiene, smoking habits, diabetes. Moreover, the demands of prosthetic, preventive and surgical dentistry will also contribute to this market. However, the lack of proper reimbursement and the high cost of dental procedures hinder the market growth.Dental equipments are the tools that help to treat, examine, manipulate and restore any oral ailments. In the United States, there has been a surge in the number of dental implant and surgeries performed due to the growing ageing populace. The most common dental procedures include root canal, periodontal, bonding, and fillings.COVID-19 effect on United States Dental IndustryDentistry is facing its most challenging time in recent history with the outbreak of coronavirus disease. The COVID-19 pandemic has effectively closed approximately 198 thousand dental doctors and active dentists in the USA. Since dental surgeons are at the highest risk of contracting the Coronavirus, with the pandemic still at large, the USA's dental market will not be able to revive in its pre-pandemic phase in 2021. But with the speeding of COVID vaccine shots, we expect the USA dental market to start recovering from the second half of 2021. Key Topics Covered: 1. Introduction2. Research & Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges4.3 Opportunities5. United States Dental Market6. Market Share - United States Dental Market6.1 Segments6.2 Dental Equipment Types7. Segments - United States Dental Market7.1 Preventive7.2 Restorative7.3 Implants7.3.1 Titanium7.3.2 Zirconium7.4 Prosthetics7.5 Endodontics7.6 Orthodontics7.7 Equipment8. Types - United States Dental Equipments Market8.1 Dental Radiology Equipments8.2 Dental Lasers8.3 Systems & Parts8.4 Laboratory Machines8.5 Hygiene Maintenance Device8.6 Other Equipments9. Dental Expenses - United Dental Market9.1 Private Insurance9.2 Out of Pocket9.3 Medicaid9.4 Public Health9.5 Others10. End Users - United States Dental Market10.1 Private10.2 Public11. Company Analysis11.1 Danaher Corporation11.1.1 Overview11.1.2 Initatives11.1.3 Sales11.2 Dentsply Sirona11.2.1 Overview11.2.2 Initatives11.2.3 Sales11.3 Henry Schein11.3.1 Overview11.3.2 Initatives11.3.3 Sales11.4 Zimmer Holdings Inc.11.4.1 Overview11.4.2 Initatives11.4.3 Sales11.5 Biolase11.5.1 Overview11.5.2 Initatives11.5.3 Sales For more information about this report visit https://www.researchandmarkets.com/r/d0vkcr CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Biotech investors live and die by the binary news events generated by the drugmakers they invest in. Heron Therapeutics (NASDAQ: HRTX), for instance, is awaiting a decision from the Food and Drug Administration about its candidate HTX-011 for use in post-operative pain. Likewise, Alkermes (NASDAQ: ALKS) expects an FDA decision on its schizophrenia and bipolar treatment ALKS3831 on or before June 1.
The "Hemoglobin Testing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Chicago IL, May 07, 2021 (GLOBE NEWSWIRE) -- FOMO CORP. (https://www.fomoworldwide.com/ - US OTC: FOMC) is pleased to announce that it has received confirmation from FINRA (the “Financial Industry Regulatory Authority” corporation) that the pending Company name change and ticker change to “FOMO CORP. / FOMC” from “2050 Motors, Inc. / ETFM” will be effective today, May 7, 2021, on or around the market open. This corporate action opens a new chapter for the company as it allows FOMO to shed the connection to its prior business, which had nothing to do with today’s focus on technology business incubation and acceleration launched two years ago. Management believes the move is a watershed event and will eliminate confusion among existing and future stakeholders. The Company continues to perform due diligence on announced and planned acquisitions, is reviewing potential investments in other technology businesses, and is in discussions with institutional investors and advisors to finance growth, though there can be no assurances. Said Dr. Wayman Baker, PhD, FOMO’s EVP for Corporate Development and Investor Relations: “I am proud to have had a role in completing this corporate action and would like to thank our legal counsel and the analyst and committee at FINRA who most recently handled our case for their dedication and professionalism.” Vik Grover, CEO of FOMO, commented: “Completing this corporate action is a major step for FOMO as we seek to expand our investment portfolio, which today is heavily focused on capabilities in Clean Technology that make buildings smarter, healthier, and more energy efficient but also has a sizable pipeline under review. This event was several months in the making, and I would like to thank our teammates and advisors for their assistance and our shareholders for their patience. Now more than ever, we are laser focused on the future and I am excited for what will come next.” In other corporate news, the March 31, 2021 quarterly financials are being reviewed by FOMO’s audit firm and are on schedule to be filed by the May 17, 2021 deadline, though there can be no assurances. Federal and State tax returns for fiscal years 2018, 2019, and 2020 will soon be filed, substantiating a significant net operating loss carry forward (“NOL”) which will potentially be a valuable tax offset in 2021-2022+ while strengthening FOMO’s financial reporting.” About FOMO CORP. FOMO CORP. is a publicly traded company focused on business incubation and acceleration. The Company invests in and advises emerging companies aligned with a growth mandate. FOMO is developing direct investment and affiliations - majority- and minority-owned as well as in joint venture formats - that afford targets access to the public markets for expansion capital as well as spin-out options to become their own stand-alone public companies. For further information on the Company and its closed and planned acquisitions see the following: https://www.fomoworldwide.com/ (public company website),https://purgevirus.com/ (stock purchase closed),https://independenceled.com/ (asset purchase closed), https://energyintelligencecenter.com/ (asset purchase closed), https://smartguard-energy.com/ (definitive agreement signed), https://www.luxsolutions.com/ (definitive agreement signed),https://www.ecoliteled.com/ (letter of intent signed). Forward Looking Statements: Statements in this press release about our future expectations, including without limitation, the likelihood that FOMO CORP. will be able to meet minimum sales expectations, be successful and profitable in the market, bring significant value to FOMO CORP.’s stockholders, and leverage capital markets to execute its growth strategy, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law. FOMO’s business strategy described in this press release is subject to innumerable risks, most significantly, whether the Company is successful in securing adequate financing. No information in this press release should be construed in any form shape or manner as an indication of the Company’s future revenues, financial condition, or stock price. Contacts: Wayman Baker, PhDEVP Corporate Development and Investor RelationsFOMO CORP.firstname.lastname@example.org://www.fomoworldwide.com/ Dwain SchenckMedia Contact203-223-5230 email@example.com
Former Vote Leave chief says Labour leader is playing SW1’s ‘lobby game’ and doing it badly
Apple is providing more details about its Apple Card Family in a new support document containing terms and conditions.
The "Hyaluronic Acid-based Dermal Fillers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Major players in the telemedicine services market are AMD Global Telemedicine, Inc, Philips Healthcare, Cisco Systems, Inc, McKesson Corporation, Allscripts Healthcare Solutions Inc. , GE Healthcare Ltd.New York, May 07, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Telemedicine Services Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06070201/?utm_source=GNW , Cerner Corporation, BioTelemetry Inc. and Teladoc.The global telemedicine services market is expected grow from $48.4 billion in 2020 to $55.53 billion in 2021 at a compound annual growth rate (CAGR) of 14.7%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $105.77 billion in 2025 at a CAGR of 17%.The telemedicine services market consists of sale of telemedicine services and related products.Telemedicine services are health care services provided via video chat, phone calls, and text messages.Patients can use telemedicine for physical examination as well as to ask questions regarding health concerns.Breach in the data makes the patients uncomfortable on sharing personal information that would help the physicians to diagnose the patients’ health, affecting the telemedicines market negatively.Telemedicine services are provided online or through calls and might not have much security for storing the data, or in some cases the telemedicine companies may use third-party servers to store the customer data to cut down the maintenance cost, which might lead to easy data breaches.For instance, in 2019, the USA has reported around 41 million healthcare records breached, with a single hacking incident affecting close to 21 million records.Rising cases of COVID 19 infections across the globe is driving the telemedicine services market.As of December 2020, the total number of active cases around the world is around 19,649,961 million, and expected to increase until the availability of vaccines.Telemedicine services will provide healthcare services to the COVID 19 affected people as they cannot step out to avail the services. Rising cases of COVID 19 infections across the globe is expected to boost the demand for the telemedicine services market.The telemedicine services market covered in this report is segmented by technology outlook into store and forward; real time and by application into teleradiology; telepsychiatry; telepathology; teledermatalogy; telecardiology.Telemedicine is increasingly being accepted and insurance companies and government-regulated health care programs are increasingly covering telemedicine services in their plans.The governments are probing companies to make changes to the policies to cover the services under their schemes.For instance, in March 2020, in response to the corona virus outbreak, the USA government announced that private insurers will be covering the cost of coronavirus testing and telemedicine services for patients.In March 2019, Teladoc health, a leading virtual care provider announced plans to acquire MédecinDirect for undisclosed amount.This acquisition will expand the geographical presence of Teladoc Health and help cover more patients in France.MédecinDirect is a leading telemedicine service provider in France.Read the full report: https://www.reportlinker.com/p06070201/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
Small biotech Ocugen (NASDAQ: OCGN) hopes to join the group. In this Motley Fool Live video recorded on April 28, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether Ocugen has a real shot at becoming a winner in the U.S. COVID vaccine market. Keith Speights: It looks like Pfizer and BioNTech are very close to finalizing a deal with the European Union to supply up to 1.8 billion doses of their COVID-19 vaccine through 2023, so it's a multiyear deal.
In times like these, investing in passively managed exchange-traded funds, or ETFs, can seem a bit dull. Let's acknowledge that investing in ETFs isn't going to make your net worth skyrocket tomorrow. Although there are a handful of ETFs that are actively managed — Cathie Wood's ARK Invest ETFs, for example — most ETFs are passively managed, which means they don't have a human manager choosing the investments.
Taiwan's top court on Friday said some hunting restrictions placed on the island's Indigenous inhabitants were unconstitutional, but stopped short of supporting the complete overhaul of regulations that campaigners had pushed for.
Miraculous mists for fuss-free application
Maria Jane Rawlings’s body was discovered by man walking dog in afternoon, police say
Arsenal have failed to qualify for Europe for the first time in 25 years
Dublin, May 07, 2021 (GLOBE NEWSWIRE) -- The "Trastuzumab Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Major players in the trastuzumab biosimilar market are Amgen Inc., Pfizer Inc, Samsung Bioepis, Merck & Co., Biocon Limited, Mylan Inc., BioXpress Therapeutics, Celltrion, Teva Pharmaceutical Industries Ltd. and EirGenix, Inc. The global trastuzumab biosimilars market is expected to decline from $1.27 billion in 2019 to $1.25 billion in 2020 at a compound annual growth rate (CAGR) of -1.50%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $3.12 billion in 2023 at a CAGR of 35.50%.The trastuzumab biosimilar market covered in this report is segmented by product into ogivri; herzuma; ontruzant; trazimera; others. It is also segmented by indication into adjuvant breast cancer; metastatic breast cancer; metastatic gastric cancer; others and by distribution channel into hospital pharmacy; online pharmacy.In April 2019, Sandoz, a generic pharmaceutical company and a subsidiary of Novartis signed an agreement with EirGenix, Taiwan-based contract development and manufacturer, to market a proposed trastuzumab biosimilar for an undisclosed amount. The agreement gives rights to Sandoz to commercialize the trastuzumab biosimilar developed by EirGenix, available globally, excluding China and Taiwan. The terms included in the agreement are that the trastuzumab will be developed and manufactured by EirGenix while Sandoz will maintain the rights to the commercialization of the drug upon approval. This agreement is expected to keep in house resources of Sandoz focused on bringing robust internal pipeline products and expanding the existing portfolio of four oncology biosimilars.The side effects of trastuzumab biosimilar are expected to limit the growth of the trastuzumab biosimilar market. The side effects of Herceptin (chemical name: Trastuzumab) include diarrhea, nausea, fever, heart problems, infection, cough, and rashes. Moreover, breast cancer studies reflect that the exposure of trastuzumab (Herceptin) therapy increased the rate of asymptomatic cardiac dysfunction in the two-year trastuzumab treatment from 4.6% to 8.1%. The rate of at least one patient experienced Grade-3 or higher, for treatment with trastuzumab is at 20.4% for two years, compared to 16.1% for one year of treatment. The side effects of trastuzumab have a negative impact on the trastuzumab biosimilar market.Major players are continuously focusing on launching new products in the untapped regions, which is shaping the market for trastuzumab biosimilars. The companies operating in the trastuzumab biosimilars market are undergoing various strategic initiatives such as new product development, partnerships, geographical and product portfolio expansion to maintain their competitive position in the market and better serve the needs of the customers. For instance, in December 2019, Biocon and Mylan launched Ogivri (trastuzumab-dkst), Trastuzumab Biosimilar in the USA. Mylan plans to offer Ogivri in 150 mg and 420mg strengths, increase access for the treatment of HER2-positive breast and gastric cancer. In February 2020, Pfizer launched trastuzumab biosimilar to Herceptin, Trazimera in the USA. Trazimera is available for the treatment of human epidermal growth factor receptor 2 (HER2) metastatic gastric and breast cancer. Furthermore, in April 2020, Merck announced the launch of a Biosimilar of Herceptin (trastuzumab)- ONTRUZANT(trastuzumab-dttb). ONTRUZANT is available in the USA for approximately $1,325 and $3,709 for the 150 mg single-dose and 420 mg multiple-dose vial, respectively.The rising prevalence of breast and gastric cancer contributed to the growth of the trastuzumab biosimilar market. Trastuzumab biosimilar is used in the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. According to the World Health Organization (WHO), in 2018, the new breast cancer cases registered were around 2.09 million, and stomach (gastric) cancer cases were around 1.03 million. According to Cancer India, breast cancer is the most common cancer in women in India and accounts for 14% of the cancers in women. Therefore, the rising prevalence of breast and gastric cancer increases the demand for trastuzumab biosimilar that helps save money when compared to expensive medicines, thereby driving the market.Key Topics Covered: 1. Executive Summary 2. Trastuzumab Biosimilars Market Characteristics 3. Trastuzumab Biosimilars Market Size And Growth 3.1. Global Trastuzumab Biosimilars Historic Market, 2015 - 2019, $ Billion3.2. Global Trastuzumab Biosimilars Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion4. Trastuzumab Biosimilars Market Segmentation 4.1. Global Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion OgivriHerzumaOntruzantTrazimeraOthers 4.2. Global Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion Adjuvant Breast CancerMetastatic Breast CancerMetastatic Gastric CancerOthers 4.3. Global Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion Hospital PharmacyOnline Pharmacy 5. Trastuzumab Biosimilars Market Regional And Country Analysis 5.1. Global Trastuzumab Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion 5.2. Global Trastuzumab Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion Companies Mentioned Amgen Inc.Pfizer IncSamsung BioepisMerck & Co.Biocon LimitedMylan Inc.BioXpress TherapeuticsCelltrionTeva Pharmaceutical Industries Ltd.EirGenix, IncALTEOGEN Inc.Apotex (Apobiologix)AryoGen PharmedBIOCADPrestige BioPharma (PBP)PlantFormOutlook Therapeutics (Oncobiologics)Shanghai CP Guojian PharmaceuticalShanghai Henlius BiotechStada Arzneimittel For more information about this report visit https://www.researchandmarkets.com/r/qvzi39 CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
The film shuns the aesthetics of Paul W S Anderson’s 1995 film – tacky, but at least imaginative – and instead assumes this is simply the first instalment of a massive and self-important franchise
At least two private equity funds are seeking to acquire stakes in Venezuelan companies that have survived the country's economic crisis, spurred in part by optimism that the Biden administration could ease sanctions on the South American nation, according to a dozen sources familiar with the talks. The interest by funds, including Miami-based 3B1 Guacamaya Fund and Cayman Islands-based Knossos Asset Management, follows Venezuelan President Nicolas Maduro's abrupt 2019 liberalization of the economy https://www.reuters.com/article/us-venezuela-shops-idCAKBN1YK16X amid a sanctions program created by former U.S. President Donald Trump. Maduro's unexpected overhaul scrapped a price control system and permitted dollar transactions for the first time in decades, allowing a small group of firms to emerge from the wreckage of a four-year hyperinflationary crisis that prompted many multinationals to leave https://t.co/I8H1Kakhhs?amp=1 the country or sell subsidiaries.
A woman who gained notoriety for refusing to wear a face mask in public during the circuit breaker while claiming that she was a “sovereign” above the law in two viral videos last year was on Friday (7 May) jailed for two weeks and fined $2,000.